Related Experiment Videos
[New development in clinical bone marrow transplantation in leukemia]
Schweizerische Medizinische Wochenschrift
|December 12, 1981
Summary
Bone marrow transplants (BMT) for leukemia show improved survival rates when performed under optimal conditions, particularly in first remission. Cyclosporin-A (CyA) effectively prevents graft-versus-host (GvH) reactions, making BMT a leading treatment for eligible leukemia patients.
Area of Science:
- Hematology
- Oncology
- Immunology
Context:
- Bone marrow transplantation (BMT) is a critical treatment for leukemia.
- Historical BMT outcomes were poor due to high mortality from graft-versus-host (GvH) reactions, interstitial pneumonia, and leukemia relapse.
- Chemotherapy exhaustion preceded BMT in historical controls, indicating late-stage disease.
Purpose:
- To evaluate the efficacy and safety of BMT for leukemia under optimized conditions.
- To assess the impact of cyclosporin-A (CyA) on GvH reaction prophylaxis.
- To compare outcomes of BMT in first remission versus later stages of leukemia.
Summary:
- Thirty-nine clinical bone marrow transplants (BMT) for leukemia were analyzed.
- Patients transplanted in first remission with CyA prophylaxis showed a 91% leukemia-free survival.
- BMT in later remission stages yielded a 50% leukemia-free survival, with deaths from relapse and CMV infection.
- CyA use significantly reduced severe GvH reactions, and BMT under optimal conditions minimizes early mortality and relapse risk.
Impact:
- Optimized BMT protocols, including CyA for GvH prophylaxis, significantly improve leukemia patient survival.
- BMT is established as the treatment of choice for leukemia patients with histocompatible sibling donors.
- Reduced GvH reactions and lower relapse rates enhance the overall success of BMT in leukemia management.